Form 4 holding
President & Chief Executive Officer, Director
Fulcrum Therapeutics, Inc.
- Security class
- Stock option - Right to Buy
- Shares / value
- 650,000
- Estimated value
- Report date
- 02 Feb 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount